Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
pritelivir br Materials and methods br Results br Discussion
2022-08-02
Materials and methods Results Discussion Main results obtained in this work are presented in Table 1 and can be summarized as follows: 1) AEA inhibits FcεRI receptor-induced degranulation with the participation of CB2 and GPR55 receptors by a PTX-insensitive mechanism; 2) AEA does not block
-
The compounds described in this paper
2022-08-02
The compounds described in this paper were prepared using a modular approach that allowed diversification of R or R at the final step (). Route A involved amide coupling of -butyl 4-(methylamino)piperidine-1-carboxylate with phenyl acetic acids (step a) using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-m
-
In order to elucidate the mechanisms behind the
2022-08-02
In order to elucidate the mechanisms behind the observed changes in metabolic activity in the cardiomyoblasts we investigated changes in gene and protein expression subsequent to treatment with PSN632408 with or without concurrent exposure to palmitate. Activating GPR119 in basal and high palmitate
-
br TGR Agonists br FXR TGR Dual
2022-08-02
TGR5 Agonists FXR/TGR5 Dual Agonists In 2010, a FXR/TGR5 dual agonist, 51 (INT-767), was reported [57]. Using an AlphaScreen coactivator recruitment assay, the potency of 51 at FXR was 30nM. In NCI-H716 cells, 51 stimulated intracellular cAMP secretion with an EC50 of 0.63μM. Its TGR5 potency
-
The original Bee Synch methodology now termed
2022-08-02
The original Bee Synch methodology (now termed Bee Synch I) utilizes a 5-day CIDR, GnRH (GnRH-1) and PGF on day 0, double dose of PGF on day 5, and FTAI with GnRH (GnRH-2) at 66 h after CIDR removal. Cruppe et al. (2014) reported that the inclusion of GnRH on day does not contribute appreciably to f
-
With these cyclopropene glutamate derivatives in hand we
2022-08-02
With these cyclopropene-glutamate derivatives in hand, we tested their ability to ligate with popular bioorthogonal reagents (Fig 3). First, we tested their ability to ligate with a tetrazine (3,6-Di-2-pyridyl-1,2,4,5-tetrazine) via an inverse electron demand Diels-Alder reaction by monitoring the c
-
br Introduction Glucagon is a peptide hormone
2022-08-02
Introduction Glucagon is a peptide hormone that acts to increase blood glucose levels. The secretion of glucagon from the alpha Escitalopram Oxalate of the islets of Langerhans in the pancreas is increased during fasting and prevents hypoglycemia. Glucagon increases glycogenolysis and gluconeoge
-
However ghrelin has a short half
2022-08-02
However, ghrelin has a short half-life of 15–20 min, because it is a natural peptide containing 28-amino acids, its clinical usefulness as a therapeutic agent may be limited (Mosińska et al., 2017; Vestergaard et al., 2007). Hence, many efforts have been made to elucidate the smallest segment of ghr
-
For the two KO models
2022-08-02
For the two KO models (CX30 and CX43), fluorescence recovery is almost always best fitted with a 2-component exponential (Fig. 6A and D). Statistical analysis of the parameters (Table 1) shows that in both cases the two time scales and the fraction of recovery associated with the fast intracellular
-
Two intermediate compounds A and B
2022-08-02
Two intermediate compounds (A and B in Fig. 1) were tested for both Aβ40 and CYP3A4 inhibition activity. Potential hydrolysis of structures I and IIin vivo may produce A which is a strong CYP3A4 inhibitor. Cyclopropanol group is a suspected liability, because INCB3344 B without it has a clean CYP3A
-
br Conclusions br Acknowledgments This study
2022-08-02
Conclusions Acknowledgments This study was supported by funds from the National Natural Science Foundation of China (NSFC 31360245, 31460258) and the Applied Basic Research Foundation of Yunnan Province of China (2011FZ111). Introduction Acute myocardial infarction is the undoubted cause o
-
g-quadruplex We found that silymarin induced more improvemen
2022-08-02
We found that silymarin induced more improvement of renal functions compared to Rvs. Our results were in agreement with previous studies. The effect of silymarin has been tested in alloxan-induced diabetes mellitus models in rats. Alloxan produces reactive oxygen species which injure renal tissue. S
-
In addition to attenuating joint inflammation
2022-08-02
In addition to attenuating joint PSI-7977 via T cells, Cpd43 could also decrease the severity of CIA/AIA by suppressing the function of innate leukocytes such as neutrophils and macrophages via FPRs, as has been shown in other acute inflammatory models including neutrophil/macrophage-mediated K/B ×
-
The pharmacokinetic properties of were amenable to oral
2022-08-02
The pharmacokinetic properties of 12 were amenable to oral dosing allowing in vivo comparison to 6. Compared to a maximum efficacious dose of 6 (60mg/kg), 12 demonstrated improved glycemic control during OGTT in high-fat fed/STZ treated (HF/STZ) and BDF/diet-induced obesity (DIO) mouse models of typ
-
We also intended to determine the possible mechanism
2022-08-02
We also intended to determine the possible mechanism underlying EZH2 upregulation in the PC. Although no recurrent mutations of EZH2 have been described in CLL [27, 28, 29], we aimed to rule out the possibility of activating mutations in the background of EZH2 overexpression. We detected no mutation
15778 records 370/1052 page Previous Next First page 上5页 366367368369370 下5页 Last page